Concurrent chemoradiation for patients with squamous cell carcinoma of the cervical esophagus

Uno, Takeji; Isobe, Koichi; Kawakami, Hiroyuki; Ueno, Naoyuki; Shimada, Hideaki; Matsubara, Hisahiro; Okazumi, Shinichi; Nabeya, Yoshihiro; Shiratori, Tooru; Kawata, Tetsuya; Ochiai, Takenori; Ito, Hiroyuki

doi:10.1111/j.1442-2050.2007.00632.x

Cited by 55 publications

(41 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These series were heterogeneous in terms of RT techniques, CHT regimens, and radiation doses. Approximately 59% of patients within these reports [6, 13, 15, 19, 26–28] received RT alone, and 41% received CRT [7, 13, 14, 16, 19, 26–29]. When a concurrent treatment approach was chosen, 22% of these patients received ICHT [16, 20, 29].…”

Section: Discussionmentioning

confidence: 99%

“…Boost HDR 2x433%/2years; 19%/3years40NANOBurmeister et al; 2000 [12]34between cricoid and upper thoracic inlet. Extension allowedRCTNO50.4-65/NA88%125NANOYamada et al; 2006 [15]27NARCT (23)NO44-73.7/1.8-252%150Performance Status/Tumor lenghtNOWang et al; 2006 [18]35tumor located above the carinaRCTVarious: platinum-based + 5-FU/paclitaxel/etoposide24.5-64.8/1.847.7%/5yearsNANADose (>50Gy)NOUno et al; 2007 [14]21cricopharyngeal muscle to thoracic inletRCTNO40/2; Boost 20-34/NA52%9NAT-Stage, initial LC5/21Huang et al; 2008 [13]71 (50 curative intent)NARCTNO54/2.7 or 50-56/2 + Boost 14-20/237%/47% (curative group)/2years24/71NAGender, Age (>64)NOChou et al; 2010 [42]29 (14 RT)NARCTNO65 (60-75)/1.8-2NANANANA15/29Ma et al; 2011 [43]33 (69 upper thoracic esophagus)NARCTNO50.4 + Boost 9 or 59.4/each 1.8 (41.4), then 2x1.5 (18)80%/86%/3years6128NATong et al; 2011 [7]107 (21 RT)NARCTNO40-46 or 60-68/2NA8NANA68/107Cao et al; 2015 [28]115NART (80)/RCT (35)NO59.4-76/1.8-2.1283%/2years282Dose (>66 Gy)10/115Gikka et al; 2013, [20]55cricopharyngeus muscle to thoracic inlet (ca. 15 - 18 cm from the incisors)RCT…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Outcome of proximal esophageal cancer after definitive combined chemo-radiation: a Swiss multicenter retrospective study

et al. 2017

View full text Add to dashboard Cite

ObjectiveTo report oncological outcomes and toxicity rates, of definitive platin-based chemoradiadiationtherapy (CRT) in the management of proximal esophageal cancer.MethodsWe retrospectively reviewed the medical records of patients with cT1-4 cN0-3 cM0 cervical esophageal cancer (CEC) (defined as tumors located below the inferior border of the cricoid cartilage, down to 22 cm from the incisors) treated between 2004 and 2013 with platin–based definitive CRT in four Swiss institutions. Acute and chronic toxicities were retrospectively scored using the National Cancer Institute’s Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE-NCI v.4.0). Primary endpoint was loco-regional control (LRC). We also evaluated overall survival (OS) and disease-free survival (DFS) rates. The influence of patient- and treatment related features have been calculated using the Log-rank test and multivariate Cox proportional hazards model.ResultsWe enrolled a total of 55 patients. Median time interval from diagnosis to CRT was 78 days (6–178 days). Median radiation dose was 56Gy (28–72Gy). Induction chemotherapy (ICHT) was delivered in 58% of patients. With a median follow up of 34 months (6–110months), actuarial 3-year LRC, DFS and OS were 52% (95% CI: 37–67%), 35% (95% CI: 22–50%) and 52% (95% CI: 37–67%), respectively. Acute toxicities (dysphagia, pain, skin-toxicity) ranged from grade 0 – 4 without significant dose-dependent differences. On univariable analyses, the only significant prognostic factor for LRC was the time interval > 78 days from diagnosis to CRT. On multivariable analysis, total radiation dose >56Gy (p <0.006) and ICHT (p < 0.004) were statistically significant positive predictive factors influencing DFS and OS.ConclusionDefinitive CRT is a reliable therapeutic option for proximal esophageal cancer, with acceptable treatment related toxicities. Higher doses and ICHT may improve OS and DFS and. These findings need to be confirmed in further prospective studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Outcome of proximal esophageal cancer after definitive combined chemo-radiation: a Swiss multicenter retrospective study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…10,11 CDDP and 5-FU have been the standard chemotherapeutic agents in combination with radiotherapy for unresectable locally advanced thoracic esophageal cancer. 25,26 As for CRT regimens containing DOC, Font et al reported weekly DOC in combination with 66 Gy of radiation for unresectable thoracic esophageal cancer, and MST, 1-year OS, and 3-year OS were 5 months, 22%, and 0%, respectively. [20][21][22][23][24] Major toxicities were leukopenia, anemia, thrombocytopenia, esophagitis, and fistula formation.…”

Section: Discussionmentioning

confidence: 99%

Role of definitive chemoradiotherapy using docetaxel and 5-fluorouracil in patients with unresectable locally advanced esophageal squamous cell carcinoma: a phase II study

et al. 2015

View full text Add to dashboard Cite

Definitive chemoradiotherapy (CRT) with docetaxel (DOC) and 5-fluorouracil (5-FU) is a unique regimen for esophageal cancer. In this prospective phase II study, antitumor effect and safety of CRT using DOC and 5-FU for inoperable locally advanced esophageal cancer were evaluated. DOC 7.5 mg/m was infused on days 1, 8, 22, and 29. 5-FU 250 mg/m /day was infused continuously on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, and 43-45. Radiotherapy was given to 66 Gy in 33 fractions. Eleven patients with thoracic and five with cervical esophageal cancer were eligible. All patients had esophageal squamous cell carcinoma (ESCC). The response rate was 94%, with complete response in five patients (31%) and partial response in 10 (63%). Hematologic toxicity was mild; only one patient (6%) had Grade 1 leukopenia. Nonhematologic Grade 3 or higher adverse events were esophagitis (31%), anorexia (6%), and esophago-bronchial fistula (6%). No treatment-related deaths occurred. The median time to progression was 20 months and overall 3-year and 5-year survival were 44% and 31%, respectively. Definitive CRT using DOC and 5-FU could be performed safely, and it demonstrated a favorable antitumor effect for ESCC. This regimen might be indicated in patients in whom it is desirable to avoid myelosuppression and progression of renal impairment.

show abstract

“…For most patients with cervical esophageal cancer, radical surgery has mandated simultaneous total laryngectomy. Therefore, most patients with cervical esophageal cancer prefer CCRT to surgery due to the potential for laryngeal preservation [8]. In reality, however, not a few patients have experience a residual or recurrent tumor after CCRT.…”

Section: Discussionmentioning

confidence: 99%

Early and long-term morbidity after minimally invasive total laryngo-pharyngo-esophagectomy with gastric pull-up reconstruction via thoracoscopy, laparoscopy and cervical incision

Homma

Nakamaru

Hatakeyama

et al. 2014

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

Total laryngo-pharyngo-esophagectomy (TLPE) with gastric pull-up reconstruction is still considered to be associated with major complications and a significant risk of in-hospital death. Minimally invasive esophagectomy, avoiding thoracotomy and laparotomy, has been increasingly performed for esophageal malignancies with the hope of reducing mortality and morbidity, such as pulmonary complications. The aim in this study was to assess early and long-term morbidity as well as treatment outcomes in patients treated with TLPE with gastric pull-up reconstruction via thoracoscopy, laparoscopy and cervical incision. From 2004 to 2013, 10 patients with a median age of 64 years (range 47-71 years) underwent minimally invasive TPLE with gastric pull-up reconstruction. Seven of the 10 patients had previously received radiotherapy. As for early postoperative complications, no patient died during the early postoperative period, and pneumonia was observed in 1, skin necrosis in 1, pseudomembranous enterocolitis in 1, arrhythmia in 2, hemorrhage in the neck in 2, anastomotic leakage in the neck in 3, and tracheal necrosis in 6 patients. Three patients developed tracheostomal stenosis as a long-term postoperative complication, and an anastomotic stricture was observed in one patient. All patients were able to achieve oral intake, but 3 patients required feeding tube support. In conclusion, postoperative systemic complications during the early postoperative period were considered to be acceptable, although wound complications such as tracheal necrosis and anastomotic leakage were commonly observed. Therefore, this minimally invasive procedure might help reduce mortality and morbidity in patients requiring TLPE with gastric pull-up reconstruction

show abstract

Concurrent chemoradiation for patients with squamous cell carcinoma of the cervical esophagus

Cited by 55 publications

References 14 publications

Outcome of proximal esophageal cancer after definitive combined chemo-radiation: a Swiss multicenter retrospective study

Outcome of proximal esophageal cancer after definitive combined chemo-radiation: a Swiss multicenter retrospective study

Role of definitive chemoradiotherapy using docetaxel and 5-fluorouracil in patients with unresectable locally advanced esophageal squamous cell carcinoma: a phase II study

Early and long-term morbidity after minimally invasive total laryngo-pharyngo-esophagectomy with gastric pull-up reconstruction via thoracoscopy, laparoscopy and cervical incision

Contact Info

Product

Resources

About